ArticleRomanian journal of ophthalmology
MOGAD-Associated Recurrent Optic Neuritis Unresponsive to Corticosteroids: Clinical, Visual Field, and OCT Correlation.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune demyelinating disorder. In adults, optic neuritis is the most common initial manifestation. Case presentation: We report the case of a 23-year-old woman presenting with right eye vision loss and severe optic disc edema. The condition was unresponsive to intravenous corticosteroids. Plasmapheresis led to marked improvement. Two months later, a second episode occurred in the left eye, despite ongoing steroid therapy. Investigations: Initial brain and orbital MRI were normal. Optical coherence tomography (OCT) showed increased RNFL thickness in the acute phase and progressive thinning during follow-up. Anti-MOG antibodies were detected at a 1:100 titer in serum, confirming the diagnosis. Treatment and outcome: The patient was treated with plasmapheresis, oral steroids, and azathioprine during the first attack. After the second relapse, rituximab was initiated. The patient achieved visual recovery and has remained relapse-free for two years. Conclusion: Corticosteroid-unresponsive recurrent optic neuritis should prompt evaluation for MOGAD, especially in the presence of bilateral involvement and optic disc edema. OCT is valuable for monitoring disease activity and structural damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.